OBJECTIVES: To assess treatment patterns and disease severity of psoriasis patients receiving their first biologic-therapy in EU. METHODS: A medical chart-review study of psoriasis patients was conducted in 4Q2013 in EU5 (UK/Germany/France/Italy/Spain) among dermatologists to collect de-identified data on disease/treatment characteristics. Physicians were screened for duration-of-practice (3-30yrs) and patient-volume (≥2psoriasis biologic patients/month) and recruited from a large panel to be geographically representative in each country. Physicians abstracted the charts of next 5 consecutive psoriasis patients in their center/practice. Results from patients on their first biologic treatment were analyzed and comparisons made to EU5-averages. RESULTS: CONCLUSIONS: Among psoriasis patients receiving their first biologic-therapy, treatment patterns and disease severity varied across the EU5. Factors influencing the observed variations in treatment patterns and outcomes warrant further scrutiny to decrease patient disease burden.